Laboratorios Farmaceuticos Rovi, S.A. announced that it expects to receive funding from Jefferies International Limited and another investor
June 22, 2021
Share
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) announced it will issue up to 1,682,069 shares on June 23, 2021. The transaction included participation from Bestinver and Jefferies International Limited for 3% stake of the company. The securities issued are subjected to hold period. The expected closing date is on June 24, 2021.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
LABORATORIOS FARMACEUTICOS ROVI, S.A. 
